Tango Therapeutics, Inc.

NasdaqGM:TNGX Voorraadrapport

Marktkapitalisatie: US$421.1m

Tango Therapeutics Dividenden en inkoop

Dividend criteriumcontroles 0/6

Tango Therapeutics heeft geen dividenduitkeringen gedaan.

Belangrijke informatie

n/a

Dividendrendement

-11.5%

Terugkoop Rendement

Totaal aandeelhoudersrendement-11.5%
Toekomstig dividendrendementn/a
Dividendgroein/a
Volgende betaaldatum dividendn/a
Ex-dividenddatumn/a
Dividend per aandeeln/a
Uitbetalingsration/a

Recente updates van dividend en inkoop

Geen updates

Recent updates

Tango Therapeutics, Inc.'s (NASDAQ:TNGX) 26% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/SRatio

Oct 31
Tango Therapeutics, Inc.'s (NASDAQ:TNGX) 26% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/SRatio

Tango Therapeutics: Amgen Missteps Devalue PRMT5 Candidates Ahead Of Critical Data

Sep 10

What Tango Therapeutics, Inc.'s (NASDAQ:TNGX) 29% Share Price Gain Is Not Telling You

Sep 01
What Tango Therapeutics, Inc.'s (NASDAQ:TNGX) 29% Share Price Gain Is Not Telling You

Subdued Growth No Barrier To Tango Therapeutics, Inc. (NASDAQ:TNGX) With Shares Advancing 27%

Jun 29
Subdued Growth No Barrier To Tango Therapeutics, Inc. (NASDAQ:TNGX) With Shares Advancing 27%

Shareholders May Not Be So Generous With Tango Therapeutics, Inc.'s (NASDAQ:TNGX) CEO Compensation And Here's Why

May 30
Shareholders May Not Be So Generous With Tango Therapeutics, Inc.'s (NASDAQ:TNGX) CEO Compensation And Here's Why

Risks Still Elevated At These Prices As Tango Therapeutics, Inc. (NASDAQ:TNGX) Shares Dive 30%

Mar 19
Risks Still Elevated At These Prices As Tango Therapeutics, Inc. (NASDAQ:TNGX) Shares Dive 30%

Tango Therapeutics (NASDAQ:TNGX) Is In A Good Position To Deliver On Growth Plans

Mar 06
Tango Therapeutics (NASDAQ:TNGX) Is In A Good Position To Deliver On Growth Plans

Tango Therapeutics, Inc.'s (NASDAQ:TNGX) Share Price Could Signal Some Risk

Jan 08
Tango Therapeutics, Inc.'s (NASDAQ:TNGX) Share Price Could Signal Some Risk

Industry Analysts Just Upgraded Their Tango Therapeutics, Inc. (NASDAQ:TNGX) Revenue Forecasts By 15%

Nov 09
Industry Analysts Just Upgraded Their Tango Therapeutics, Inc. (NASDAQ:TNGX) Revenue Forecasts By 15%

New Forecasts: Here's What Analysts Think The Future Holds For Tango Therapeutics, Inc. (NASDAQ:TNGX)

Aug 12
New Forecasts: Here's What Analysts Think The Future Holds For Tango Therapeutics, Inc. (NASDAQ:TNGX)

Will Tango Therapeutics (NASDAQ:TNGX) Spend Its Cash Wisely?

May 10
Will Tango Therapeutics (NASDAQ:TNGX) Spend Its Cash Wisely?

Tango Therapeutics started at buy at Wainwright on synthetically lethal targets for cancer

Oct 20

Companies Like Tango Therapeutics (NASDAQ:TNGX) Are In A Position To Invest In Growth

Oct 05
Companies Like Tango Therapeutics (NASDAQ:TNGX) Are In A Position To Invest In Growth

Tango Therapeutics, Inc. (NASDAQ:TNGX) Second-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For This Year

Aug 13
Tango Therapeutics, Inc. (NASDAQ:TNGX) Second-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For This Year

Tango Therapeutics GAAP EPS of -$0.28 beats by $0.03, revenue of $5.78M beats by $0.12M

Aug 10

We're Not Worried About Tango Therapeutics' (NASDAQ:TNGX) Cash Burn

May 28
We're Not Worried About Tango Therapeutics' (NASDAQ:TNGX) Cash Burn

We're Interested To See How Tango Therapeutics (NASDAQ:TNGX) Uses Its Cash Hoard To Grow

Jan 06
We're Interested To See How Tango Therapeutics (NASDAQ:TNGX) Uses Its Cash Hoard To Grow

Stabiliteit en groei van betalingen

Dividenden ophalen

Stabiel dividend: Er zijn onvoldoende gegevens om te bepalen of het dividend per aandeel van TNGX in het verleden stabiel is geweest.

Groeiend dividend: Er zijn onvoldoende gegevens om te bepalen of de dividendbetalingen van TNGX zijn gestegen.


Dividendrendement versus markt

Tango Therapeutics Dividendrendement versus markt
Hoe verhoudt TNGX dividendrendement zich tot de markt?
SegmentDividendrendement
Bedrijf (TNGX)n/a
Markt onderkant 25% (US)1.3%
Markt Top 25% (US)4.2%
Gemiddelde industrie (Biotechs)2.3%
Analist prognose (TNGX) (tot 3 jaar)n/a

Opmerkelijk dividend: Het dividendrendement van TNGX kan niet worden vergeleken met dat van de onderste 25% van de dividendbetalers, aangezien het bedrijf geen recente uitbetalingen heeft gerapporteerd.

Hoog dividend: Het dividendrendement van TNGX kan niet worden vergeleken met dat van de top 25% van de dividendbetalers, aangezien het bedrijf geen recente uitbetalingen heeft gerapporteerd.


Winstuitkering aan aandeelhouders

Verdiendekking: Er zijn onvoldoende gegevens om de payout ratio TNGX te berekenen en vast te stellen of de dividendbetalingen worden gedekt door de winst.


Contante uitbetaling aan aandeelhouders

Kasstroomdekking: De duurzaamheid van het dividend kan niet worden berekend, omdat TNGX geen uitbetalingen heeft gerapporteerd.


Ontdek bedrijven met een sterk dividend